Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Deep Patel

Physician Assistant Roswell, GA Physician Assistant

NPI 1033603832 CMS profile 10413640

11685 Alpharetta Hwy, Roswell, GA 30076

Open in the dashboard

General payments

$4,319

71 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deep Patel of Roswell, GA is reported in the CMS Open Payments database as having received $4,319 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,352 14
2024 General $573 7
2023 General $367 4
2022 General $991 20
2021 General $1,036 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deep Patel
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Deep Patel were reported at $1,352. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Deep Patel Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,036 $132 $37–$438 $132
2022 $991 $155 $48–$522 $149
2023 $367 $167 $52–$557 $160
2024 $573 $178 $55–$600 $164
2025 $1,352 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Bioventus LLC $2,608 25 payments
  2. Horizon Therapeutics plc $552 27 payments
  3. Maquet Cardiovascular U.S. Sales, L.L.C. $485 6 payments
  4. Stryker Corporation $267 4 payments
  5. Flexion Therapeutics, Inc. $108 1 payment
  6. KCI USA, Inc $100 1 payment
  7. Amgen Inc. $54 1 payment
  8. Vericel Corporation $39 2 payments
  9. Vertex Pharmaceuticals Incorporated $34 1 payment
  10. OssDsign Incorporated $26 1 payment
  11. Other $46 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,965 69 payments
  2. Travel and Lodging $354 2 payments
Products named General payments · program years 2021–2025
  1. DUROLANE Orthopedicsorthopedic Surgery $769 6 payments
  2. Vasoview Hemopro 2 $485 6 payments
  3. Durolane Orthopedics/Orthopedic Surgery $464 5 payments
  4. XCELL $463 5 payments
  5. PENNSAID $325 20 payments
  6. GELSYN-3 $271 2 payments
  7. EXOGEN ULTRASOUND BONE HEALING SYSTEM Devices $261 3 payments
  8. NA $193 3 payments
  9. Exogen Ultrasound Bone Healing System Not Applicable $153 2 payments
  10. L360 Thigh System $147 1 payment
  11. Other $1,057 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

98

Median for Physician Assistant: 241

Drug cost

$467

Median for Physician Assistant: $4,110

Branded share of claims

15.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 24 $131
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 15 $114
Cyclobenzaprine Hcl Generic 15 $110
Azithromycin Generic 21 $61
Meloxicam Generic 23 $52

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$45,828

Of which drugs: $9,194

Medicare patients

346

Average age 74

Services billed

12,080

208 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 70%
High blood pressure 68%
Ischemic heart disease 32%
Diabetes 21%
Depression 16%
Atrial fibrillation 15%
Chronic kidney disease 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 13 58 $5,237
Injection, methylprednisolone acetate, 1 mg J1010 Office 41 3,762 $370
Injection, methylprednisolone acetate, 40 mg J1030 Office 11 12 $32

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record